Clinical Trial Update: A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations [Phase 1]

View source ↗

Summary

A Phase 1 trial update evaluating the pharmacokinetic exposure of Maridebart Cafraglutide (AMG 133) when administered via two subcutaneous presentations in adul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Maridebart Cafraglutide

Snippet

Sponsor: Amgen | Conditions: Overweight and Obesity | Phase 1 | Status: ACTIVE_NOT_RECRUITING